This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Benjamin Kim, MD; Patricia Warnaka; Michael Iverson, PhD; Anthony L. Imbembo, MD

Arch Surg. 1987;122(12):1455-1459.

Abstract
• Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthreneinduced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti—T-cell suppressor factor and points to possible strategies for clinical application.

(Arch Surg 1987;122:1455-1459)

Author Affiliations
From the Department of Surgery, Cleveland Metropolitan General Hospital and Case Western Reserve University School of Medicine, Cleveland (Drs Kim and Imbembo and Ms Warnaka); and the Medical Biology Institute, La Jolla, Calif (Dr Iverson).

Footnotes
Accepted for publication July 16, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 30, 1987.

Reprint requests to Department of Surgery, Cleveland Metropolitan General Hospital, 3395 Scranton Rd, Cleveland, OH 44109 (Dr Kim).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?